H&S Research Search

What do you remember?

Try a workplace, company, occupation, product, city, trust, or another detail you remember.

Start with one remembered detail.

Your search stays in your browser. Nothing you type here is submitted to H&S. Open full search →
Mesothelioma News | Treatment research

Why Mesothelioma Can Stop Responding to Chemotherapy: New Study Examines How Tumors Influence Immune Cells

A new study investigates how chemotherapy-resistant mesothelioma cells may influence nearby immune cells—and why this remains experimental research.

Published November 16, 2026 · H&S Research & News Desk

← Back to Mesothelioma News

Why does chemotherapy sometimes stop controlling mesothelioma, even when a patient initially responds to treatment?

A newly published study offers a possible explanation. Researchers found that chemotherapy-resistant mesothelioma cells can influence nearby immune cells in ways that help tumors continue growing.

The research, published November 12, 2026, in the medical journal Cancer Letters, identified a signaling pathway known as CCL5–CCR5 that appears to contribute to this process. When researchers interfered with that pathway in experimental models, tumor progression was reduced.

The findings are promising for future research, but they have not been shown to improve treatment outcomes in people with mesothelioma.

Why chemotherapy resistance matters

Chemotherapy remains an important treatment option for pleural mesothelioma, a cancer affecting the lining of the lungs. Medicines such as cisplatin and pemetrexed have long been used to treat the disease. Although some patients benefit from chemotherapy, tumors may eventually resume growing despite treatment.

Researchers call this treatment resistance. Resistance can develop through changes within cancer cells themselves. Scientists are also learning that the surrounding environment—including immune cells, connective tissue and chemical signals—may influence how tumors respond to treatment.

Understanding these interactions could help researchers identify new ways to address resistance.

What did the November study find?

Researchers led by Laura Gerardelli and colleagues investigated experimental models of pleural mesothelioma that had developed resistance to cisplatin. They examined human and mouse mesothelioma cells and studied how resistant tumors interacted with immune cells.

The resistant cancer cells produced increased amounts of a signaling protein called CCL5. CCL5 can interact with a receptor known as CCR5, which is found on certain immune cells.

The researchers found that this signaling pathway helped attract macrophages into the tumor environment. Macrophages ordinarily perform important functions, including helping the body respond to infections and damaged tissue.

However, tumors can sometimes influence macrophages in ways that support cancer growth rather than oppose it. In the experimental models, the researchers found evidence that CCL5–CCR5 signaling encouraged macrophages to develop tumor-supporting characteristics.

The result was an environment that appeared to help chemotherapy-resistant mesothelioma progress.

Could blocking this pathway help?

The research team investigated two approaches to interfering with CCL5–CCR5 signaling. One involved reducing production of CCL5 in cancer cells through genetic techniques. The other involved blocking the CCR5 receptor using maraviroc, an existing medication approved for certain HIV infections.

Both approaches reduced tumor-supporting macrophage activity and impaired tumor progression in the experimental models.

This finding is important because it suggests that researchers may be able to investigate treatment resistance by targeting not only cancer cells, but also the signals that influence surrounding immune cells.

However, the experiments do not establish that blocking CCR5 will benefit people undergoing mesothelioma treatment.

Is maraviroc an approved treatment for mesothelioma?

No. Maraviroc is an antiretroviral medication approved for certain HIV-1 infections. It is not FDA-approved to treat mesothelioma.

The November study did not demonstrate that administering maraviroc to patients with mesothelioma improves survival, shrinks tumors or prevents chemotherapy resistance. Those questions would require clinical research involving patients.

Investigators would also need to evaluate appropriate dosing, potential side effects and possible interactions with existing cancer treatments.

Patients should not begin taking maraviroc or change prescribed cancer treatment based on these experimental findings.

Is this an entirely new discovery?

The November publication builds upon earlier research by the same scientific group. Related findings concerning CCL5–CCR5 signaling and chemotherapy-resistant mesothelioma had been presented at scientific conferences before the November 12 journal publication.

The new Cancer Letters article provides a peer-reviewed account of the researchers’ experimental findings. It should therefore be understood as an important development in an ongoing research effort, rather than the first discovery of this biological pathway.

What does this mean for patients today?

For patients currently receiving chemotherapy, the study does not change established treatment recommendations. It does not provide a new clinical test that reliably predicts when mesothelioma will become resistant to chemotherapy. Nor does it establish that maraviroc or another CCR5 inhibitor should be added to an existing treatment regimen.

Patients whose mesothelioma progresses during treatment may wish to discuss several questions with their oncology team:

  • Has the cancer’s progression been confirmed through appropriate evaluation?
  • What established treatment options remain available?
  • Are there clinical trials appropriate for the patient’s diagnosis and treatment history?
  • How can symptoms, treatment side effects and quality of life be managed?

Treatment decisions depend on the individual’s circumstances, including the type of mesothelioma, previous treatments and overall health.

For additional background, readers can consult H&S’s Mesothelioma Treatment Options resource and its guide to Finding a Mesothelioma Specialist.

Why this research deserves attention

One of the continuing challenges in mesothelioma treatment is understanding why therapies that initially control the disease sometimes lose their effectiveness.

The November 12 study adds evidence that chemotherapy resistance may involve a relationship between cancer cells and the immune cells surrounding them. That relationship could eventually provide researchers with additional targets for experimental treatments.

The investigators’ findings also illustrate why studying the tumor environment may be important alongside research focused directly on cancer cells.

For now, the study identifies a potential avenue for future treatment research—not a proven new therapy for mesothelioma patients.

Original research and medical sources

Research scope: H&S reviewed the publisher’s article preview, abstract, research highlights and available methodological excerpts. The complete publisher PDF was not available for independent review. This report does not claim unverified numerical treatment effects or clinical benefit.

Medical information notice: This article discusses preclinical scientific research for general educational purposes. The findings do not establish the safety or effectiveness of an experimental mesothelioma treatment. Patients should consult qualified medical professionals before making treatment decisions. Humpleby & Strauss, P.C. is a law firm and does not provide medical treatment. Editorial standards.

Explore more Mesothelioma News and Court Developments